PSMA Binding Ligand-Linker Conjugates for Targeted Prostate Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for prostate cancer often have significant side effects due to non-specific targeting, affecting quality of life, particularly in older men, as they impact non-target tissues like bones and the liver.
Innovation Solution
Development of conjugates comprising a prostate-specific membrane antigen (PSMA) binding ligand linked to a drug or imaging agent via a linker, allowing for selective delivery and targeting of therapeutic or diagnostic agents to prostate cancer cells, minimizing impact on non-target tissues.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (hormonal therapy, radiation therapy, chemotherapy) are used to treat prostate cancer, then cancer cells are killed or controlled, but non-target tissues (bones, liver) are damaged causing significant side effects
Solution Approach 1:
The treatment approach is segmented into two distinct components: a targeting moiety (PSMA ligand) that specifically binds to prostate cancer cells, and a cytotoxic moiety (drugging agent) that kills cancer cells. This segmentation allows the cytotoxic agent to be delivered only to cancer cells expressing PSMA, sparing non-target tissues from damage.
Solution Approach 2:
The PSMA-binding ligand acts as an intermediary that mediates between the cytotoxic drug and the cancer cell. The ligand specifically binds to PSMA receptors on cancer cell surfaces, serving as a selective delivery vehicle that transports the cytotoxic agent only to the intended target, preventing off-target effects on healthy tissues.
2Productivity
If non-specific chemotherapy agents are administered systemically, then cancer cells are killed throughout the body, but quality of life deteriorates due to damage to healthy organs
Solution Approach 1:
The conjugate exhibits local quality by having different functional regions with distinct properties: the PSMA ligand portion provides high affinity and specificity for cancer cell targeting, while the cytotoxic portion provides potent cancer cell killing activity. This local differentiation of function allows selective action at the cancer site without affecting healthy tissues.
Solution Approach 2:
The invention changes the key parameter of drug distribution from non-specific systemic distribution to specific target-directed distribution. By conjugating the cytotoxic agent to a PSMA-specific ligand, the pharmacokinetic profile is altered so that the drug accumulates preferentially at cancer sites, increasing local concentration while reducing exposure of healthy organs.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates enable targeted therapy and imaging of prostate cancer cells, reducing side effects by selectively binding to PSMA-expressing cells, thereby improving treatment specificity and patient quality of life.
Implementation Method 1
PSMA binding ligand linked to a drug or imaging agent via a linker, allowing for selective delivery and targeting of therapeutic or diagnostic agents to prostate cancer cells
Data Source
AI summary
Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.